(24/7 MARKET NEWS) – Inozyme Pharma, Inc. (Nasdaq: INZY) reported, this morning, positive topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE), as well as encouraging patient reported outcome data as measured by global impression of change (GIC) in the ENPP1 Deficiency trial.
Inozyme Pharma is at $2.69, up $0.47 (+21.17%), on trading volume of 1 million premarket shares.
Its 52-week trading range is $0.991 to $7.03. If it can break through its recent $3 high, its setup is favorable to potentially challenge the $4+ level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
